MBOT

Microbot Medical Inc

Add to Watchlist

Advanced Chart

3.120

+0.23(7.958%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.140

Open

2.900

VWAP

3.01

Vol

2.18M

Mkt Cap

140.17M

Low

2.900

Amount

6.56M

EV/EBITDA(TTM)

Total Shares

15.97M

99.45M

EV/OCF(TTM)

P/S(TTM)

Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.

Get winning stock picks in minutes

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.080

-52.94%

-0.080

-60%

-0.070

-65%

Estimates Revision

The market is revising No Change the revenue expectations for Microbot Medical Inc. (MBOT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 31.09%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+31.09%

In Past 3 Month

1 Analyst Rating

188.46% Upside

Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

188.46% Upside

Current: 3.120

Low

9.00

Averages

9.00

High

9.00

188.46% Upside

Current: 3.120

Low

9.00

Averages

9.00

High

9.00

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2025-04-10

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2025-04-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$7 → $9

2025-01-24

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$7 → $9

2025-01-24

Maintains

Strong Buy

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Microbot Medical Inc (MBOT.O) is -9.95, compared to its 5-year average forward P/E of -3.48. For a more detailed relative valuation and DCF analysis to assess Microbot Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.48

Current PE

-9.95

Overvalued PE

-1.67

Undervalued PE

-5.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

810.95

Current PS

20.73

Overvalued PS

5377.47

Undervalued PS

-3755.57